...
首页> 外文期刊>The oncologist >Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy.
【24h】

Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy.

机译:新辅助化疗治疗的710例可手术乳腺癌患者中,有丝分裂指数,Ki-67,细胞周期蛋白D1和环氧化酶2的变化以及预测和预后价值。

获取原文
获取原文并翻译 | 示例

摘要

The current study expands upon previous work using a database of 710 patients treated with neoadjuvant chemotherapy. First, we studied phenotypic characteristics of tumors before and after chemotherapy using the following factors: the mitotic index of the Scarff-Bloom-Richardson grade, Ki-67, cyclin D1, and cyclo-oxygenase-2. Second, the predictive value of these factors on response was assessed. Third, we measured the prognostic impact of these markers post-therapy in comparison with clinical and pathological responses according to the Chevallier and Sataloff classifications. Patients were treated using different neoadjuvant chemotherapy combinations, mainly in successive prospective phase II trials. They received a median number of six cycles (range, 1-9). After neoadjuvant chemotherapy, patients underwent surgery and radiotherapy. In cases of important residual disease, some received additional courses of chemotherapy. In addition, menopausal patients with hormone receptor-positive tumors received tamoxifen for 5 years. According to our analysis, we found significant variations before and after neoadjuvant chemotherapy only for cyclin D1 and the mitotic index. Concerning the predictive value of biomarkers for response, Ki-67 and the mitotic index were predictive on univariate analysis, both for objective clinical and pathological complete responses. Because these two factors were correlated, no multivariate analyses were conducted. We then assessed the prognostic impact of the biopathological factors. When the factors were measured before chemotherapy, all were prognostic. When evaluated after chemotherapy, the mitotic index, objective clinical response, and pathological complete response were prognostic. Because these factors were correlated, no multivariate model was done. The main clinical fact is that there were significant correlations between clinical and pathological responses and variations in the biological factors studied.
机译:当前的研究使用了710例接受新辅助化疗的患者的数据库,对以前的工作进行了扩展。首先,我们使用以下因素研究了化疗前后肿瘤的表型特征:Scarff-Bloom-Richardson等级的有丝分裂指数,Ki-67,cyclin D1和环氧合酶2。其次,评估这些因素对反应的预测价值。第三,根据Chevallier和Sataloff分类,我们测量了这些标志物在治疗后与临床和病理反应相比对预后的影响。使用不同的新辅助化疗组合治疗患者,主要是在连续的前瞻性II期试验中。他们接受了六个周期的中位数(范围为1-9)。新辅助化疗后,患者接受了手术和放疗。在重要的残留疾病的情况下,一些患者接受了额外的化学疗法。此外,激素受体阳性肿瘤的更年期患者接受他莫昔芬治疗5年。根据我们的分析,我们发现新辅助化疗前后仅针对细胞周期蛋白D1和有丝分裂指数有显着差异。关于生物标志物对反应的预测价值,Ki-67和有丝分裂指数在单变量分析中对客观临床和病理完全反应均具有预测性。因为这两个因素相关,所以没有进行多变量分析。然后,我们评估了生物病理因素对预后的影响。在化疗之前测量这些因素时,所有因素均预后良好。化疗后进行评估时,有丝分裂指数,客观临床反应和病理完全反应预后良好。因为这些因素是相关的,所以没有进行多元模型分析。主要的临床事实是临床和病理反应与所研究的生物学因素之间存在显着的相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号